JMP Securities Downgrades Cadence Pharmaceuticals (CADX) to Underperform
More News related to CADX
- Cadence Pharma (CADX) Nov volatility elevated at 174 into PDUFA
- Cadence Pharmaceuticals (CADX) Reports a Q3 Loss
- Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
More News related to Downgrades
- Trading Radar for 11/10: Tyco Int. (TYC), ArvinMeritor (ARM), Clearwire (CLWR), American Apparel (APP) Report
- Unusual 11 Mid-Day Movers 11/09: EONC, EWBC, REV, PRST Higher; GTN, CHNG, SRZ, CHDX Lower
- Notable Analyst Rating Changes: RSH, ANF, NOC, ADBE, HERO Upgraded; RIMM, RHT, GPS, AZN, SGY Downgraded
- Morning Movers 11/09: EWBC, CVM, REV, CGEN, RSH Higher; CHDX, SRZ, GTN, RPRX, VSR Lower
- Notable Mergers and Acquisitions of the Day 11/9: ERTS, GE/CMCSA, EWBC
JMP Securities downgrades Cadence Pharmaceuticals (Nasdaq: CADX) from Market Perform to Underperform.
To see more analyst ratings on CADX Click Here.
Cadence Pharmaceuticals, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates principally for use in the hospital setting in the United States and Canada.
Related Categories
DowngradesStocks Mentioned
-0.14Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
